The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor

被引:312
作者
Basu, S
Nagy, JA
Pal, S
Vasile, E
Eckelhoefer, IA
Bliss, VS
Manseau, EJ
Dasgupta, PS
Dvorak, HF
Mukhopadhyay, D
机构
[1] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
基金
美国国家卫生研究院;
关键词
D O I
10.1038/87895
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Angiogenesis has an essential role in many important pathological and physiological settings. It has been shown that vascular permeability factor/vascular endothelial growth factor (VPF/VEGF), a potent cytokine expressed by most malignant tumors, has critical roles in vasculogenesis and both physiological and pathological angiogenesis. We report here that at non-toxic levels, the neurotransmitter dopamine strongly and selectively inhibited the vascular permeabilizing and angiogenic activities of VPF/VEGF. Dopamine acted through D2 dopamine receptors to induce endocytosis of VEGF receptor 2, which is critical for promoting angiogenesis, thereby preventing VPF/VEGF binding, receptor phosphorylation and subsequent signaling steps. The action of dopamine was specific for VPF/VEGF and did not affect other mediators of microvascular permeability or endothelial-cell proliferation or migration. These results reveal a new link between the nervous system and angiogenesis and indicate that dopamine and other D2 receptors, already in clinical use for other purposes, might have value in anti-angiogenesis therapy.
引用
收藏
页码:569 / 574
页数:6
相关论文
共 41 条
  • [1] Blood vessels in liver metastases from both sarcoma and carcinoma lack perivascular innervation and smooth muscle cells
    Ashraf, S
    Loizidou, M
    Crowe, R
    Turmaine, M
    Taylor, I
    Burnstock, G
    [J]. CLINICAL & EXPERIMENTAL METASTASIS, 1997, 15 (05) : 484 - 498
  • [2] DOPAMINERGIC RECEPTORS LINKED TO ADENYLATE-CYCLASE IN HUMAN CEREBROMICROVASCULAR ENDOTHELIUM
    BACIC, F
    UEMATSU, S
    MCCARRON, RM
    SPATZ, M
    [J]. JOURNAL OF NEUROCHEMISTRY, 1991, 57 (05) : 1774 - 1780
  • [3] Dopamine, a neurotransmitter, influences the immune system
    Basu, S
    Dasgupta, PS
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2000, 102 (02) : 113 - 124
  • [4] Decreased dopamine receptor expression and its second-messenger cAMP in malignant human colon tissue
    Basu, S
    Dasgupta, PS
    [J]. DIGESTIVE DISEASES AND SCIENCES, 1999, 44 (05) : 916 - 921
  • [5] Role of dopamine in malignant tumor growth
    Basu, S
    Dasgupta, PS
    [J]. ENDOCRINE, 2000, 12 (03) : 237 - 241
  • [6] EXPRESSION OF THE VASCULAR-PERMEABILITY FACTOR VASCULAR ENDOTHELIAL GROWTH-FACTOR GENE IN CENTRAL-NERVOUS-SYSTEM NEOPLASMS
    BERKMAN, RA
    MERRILL, MJ
    REINHOLD, WC
    MONACCI, WT
    SAXENA, A
    CLARK, WC
    ROBERTSON, JT
    ALI, IU
    OLDFIELD, EH
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (01) : 153 - 159
  • [7] Evolution of the management of acute myocardial infarction: a 20th century saga
    Braunwald, E
    [J]. LANCET, 1998, 352 (9142) : 1771 - 1774
  • [8] Brown LF, 1997, REGULATION ANGIOGENE
  • [9] Progressive loss of perivascular nerves adjacent to colorectal cancer
    Chamary, VL
    Robson, T
    Loizidou, M
    Boulos, PB
    Burnstock, G
    [J]. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2000, 26 (06): : 588 - 593
  • [10] ANTITUMOR EFFECT OF IP DOPAMINE IN MICE BEARING EHRLICH ASCITES-CARCINOMA
    DASGUPTA, PS
    LAHIRI, T
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1987, 113 (04) : 363 - 368